StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Doxifluridin

Doxifluridine

HCID 18343
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
3094-09-5
Standard-SMILES
C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
InChIKey
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
Summenformel
C9H11FN2O5
Durchschnittliche Molmasse
246,19 g/mol
Monoisotopische Masse
246,06519962

Überblick

Doxifluridine is a pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase. It has a role as an antimetabolite, an antineoplastic agent and a prodrug. It is an organofluorine compound and a pyrimidine 5'-deoxyribonucleoside.

Namen und Bezeichner

Bevorzugter Name
Doxifluridine
IUPAC
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione
Lokaler Name
Doxifluridin
Englischer Name
Doxifluridine
Summenformel
C9H11FN2O5
Molmasse
246.19

Namen und Synonyme

doxifluridine5'-Deoxy-5-fluorouridine5-fluoro-5'-deoxyuridineFurtulon3094-09-5Uridine, 5'-deoxy-5-fluoro-Flutron5'-DfurDoxifluridinaDoxifluridinumFulturonRo 219738
Weitere Namen anzeigen
5'DFURDAMC 01015-F-5‘-dURO-21-97385-cl-5'-dUDoxifluidine
DTXSID2022967Uridine-5'-deoxy-5-fluoro-1-(beta-D-5-Desoxyribofuranoxyl)-5-fluoruracilRo 21-97385-DFURV1JK16Y2JPNSC-758890RO-219738

Datenbank-Bezeichner

CAS
3094-09-5
PubChem CID
18343
DTXSID
DTXSID2022967
ChEMBL
CHEMBL1130
ChEBI
CHEBI:31521
UNII
V1JK16Y2JP
EC Number
221-440-1
Nikkaji
J7.679A

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-1,7
Polarare Oberfläche (TPSA)
99,1 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
1
Schwere Atome
17
Formalladung
0
Komplexität
399

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents

Solubility>36.9 [ug/mL] (The mean of the results at pH 7.4)
Collision Cross Section150.41 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
188 · 188-192 °C(lit.)
Dichte
1.3751 · 1.3751 (estimate)
Brechungsindex
20 ° · 20 ° (C=1, H2O)
storage temp.
Inert atmosphere,Room Temperature
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
7.4 · 7.4(at 25℃)
Farbe
White
Merck
14 · 14,3437
Major Application
pharmaceutical small molecule
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
InChIKey
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
SMILES
C[C@H]1O[C@@H](N2C=C(F)C(=O)NC2=O)[C@H](O)[C@@H]1O
CAS Datenbank
3094 · 3094-09-5(CAS DataBase Reference)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 16.7% (1 of 6) of reports.

Danger

H226 (16.7%): Flammable liquid and vapor [Warning Flammable liquids]

P203, P210, P233, P240, P241, P242, P243, P261, P264, P264+P265, P271, P272, P273, P280, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P317, P318, P319, P321, P332+P317, P333+P317, P337+P317, P362+P364, P370+P378, P391, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 6 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesFlam. Liq. 3 (16.7%)

Toxikologische Informationen

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Doxifluridine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

wgk
2
hs_code
29349990
RTECS-Nr.
YU7526000
risk_code
36/37/38
Toxizität
LD50 (14 day) in mice or rats (mg/kg): >1000 i.v.: >2000 s.c.; in male, female mice, male, female rats (mg/kg): >5000, >5000, 3471, 3390 orally (Shimizu)
hazard_code
Xi
hazard_note
Irritant
safety_code
26-36-24/25
hazard_class
IRRITANT, IRRITANT-HARMFUL
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

MeSH Pharmacological Classification · 3 Einträge

Antimetabolites that are useful in cancer chemotherapy.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.

Tissue LocationsKidney
Cellular LocationsCytoplasm
Metabolite PathwaysCapecitabine Action Pathway

Anwendungen

BeschreibungDoxifluridine is a prodrug derivative of 5-fluorouracil (5-FU). As an antineoplastic it is more potent than 5-FU in the treatment of breast, stomach, colon and rectal cancers.

VerwendenAn antitumor agent efficient in tumors, cell lines or in fibroblasts tranformed by H-ras or trk oncogenes. A metabolite of Capecitabine

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Palladium carbon fine chemical catalyzerp-Toluenesulfonic acid monohydrateEthylacetatTriphenylstibinMethyljodidAceton-dimethylacetal
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluoro racil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1089416
HRID 1089416als Edukt
Reaktionsgleichung von HRID 1358063
HRID 1358063als Produkt
Reaktionsgleichung von HRID 1358065
HRID 1358065als Produkt
Reaktionsgleichung von HRID 1358067
HRID 1358067als Produkt
Reaktionsgleichung von HRID 1719780
HRID 1719780als Produkt
Reaktionsgleichung von HRID 1759378
HRID 1759378als Produkt
Reaktionsgleichung von HRID 1759379
HRID 1759379als Produkt
Reaktionsgleichung von HRID 2091456
HRID 2091456als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung